This has led to a compelling hypothesis that the cell of origin for LCH is a hematopoietic precursor and that the clinical manifestations of LCH depend on where along the differentiation pathway the oncogenic BRAF mutation occurs [1]. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.